Prescribing Patterns and Medication Problems Related to the Use of Pain Medication and Adjuvant Drugs in Patients with Osteoarthritis
Article Sidebar
Main Article Content
Abstract
Objectives: To investigate prescribing patterns and potential problems of the use of analgesics and adjuvant drugs in patients with osteoarthritis and to identify the relationships between medication problems and demographic data of patients. Methods: The study was a descriptive study with retrospective collection of data from medical records during October 1st, 2010 and September 30th, 2012 in a hospital in Northeast region. The study evaluated the potential medication problems and their causes using the drug-related problem classifications version 6.2 developed by the Pharmaceutical Care Network Europe Results: 194 patients participated in the study. The majority was female (76.3%) with 62.65 years of age. The most commonly prescribed pain medication was NSAIDs (61.5%) followed by paracetamol (24.8%) and tramadol (13.7%). The prescribing of single selective COX-2 inhibitor (29.4%) was the most common prescribing patterns. Thirty eight participants (19.6%) had potential medication problems. The most common potential medical problem was adverse drug reactions in gastrointestinal tracts (52.4%) caused by not receiving Proton Pump Inhibitors (PPIs) as recommended by the osteoarthritis guidelines. The second most common potential medication problem was suboptimal effect of drug treatment (42.6%) due to too long dosing interval of tramadol prescribed. The study found that age (r = 0.22, p <0.05), number of co-morbidities (r = 0.81, p <0.05) and type of medication (p <0.05) were significantly related to potential medication problems. Conclusion: This study provided the information on overall prescribing patterns and potential medication problems of both pain medication and adjuvant drugs in patients with osteoarthritis. The result could be used to develop pharmaceutical care services to improve the effectiveness of medication use as well as to help reduce and prevent medication problems in this group of patients.
Article Details
ผลการวิจัยและความคิดเห็นที่ปรากฏในบทความถือเป็นความคิดเห็นและอยู่ในความรับผิดชอบของผู้นิพนธ์ มิใช่ความเห็นหรือความรับผิดชอบของกองบรรณาธิการ หรือคณะเภสัชศาสตร์ มหาวิทยาลัยสงขลานครินทร์ ทั้งนี้ไม่รวมความผิดพลาดอันเกิดจากการพิมพ์ บทความที่ได้รับการเผยแพร่โดยวารสารเภสัชกรรมไทยถือเป็นสิทธิ์ของวารสารฯ
References
2. Breivik H and et al. Survey of chronic pain in Europe: Prevalence, impact on daily life, and treatment. Eur J Pain. 2006; 10: 287-333.
3. Saastamoinen P, Leino-Arjas P, Laaksonen M, Lahelma E. Socio-economic differences in the prevalence of acute, chronic and disabling chronic pain among ageing employees. Pain. 2005; 114: 364-71.
4. Thaneerat A and et al. Pain and management of pain in chronic non-cancer pain patients with musculoskeletal disorders. Songkla Med J. 2008; 26: 25-36.
5. ราชวิทยาลัยแพทย์ออร์โธปิดิกส์แห่งประเทศไทย. แนวปฏิบัติการดูแลรักษาโรคข้อเข่าเสื่อม พศ. 2553. กรุงเทพฯ: ราชวิทยาลัยแพทย์ออร์โธปิดิกส์แห่งประเทศไทย; 2553.
6. National Institute for Health and Clinical Excellence (NICE). Osteoarthritis guidelines [online] 2010. [cited 2012, Jan]. Available from: http://guidance.nice.org.uk/CG96.
7. The American Pain Society. Principal of analgesic use in the treatment of acute and cancer pain. 4th ed. Illinois: The International Association for the Study of Pain; 2004.
8. Zhang W, Jones A, Doherty M. Does paracetamol (acetaminophen) reduce the pain of osteoarthritis?: a meta-analysis of randomized controlled trials. Ann Rheum Dis. 2004; 63: 901-7.
9. Lee C and et al. A comparison of the efficacy and safety of nonsteroidal antiinflammatory agents versus acetaminophen in the treatment of osteoarthritis: a meta-analysis. Arthritis & Rheumatism 2004; 51: 746-54.
10. Manchikanti L, Manchikanti K, Pampati V, Cash K. Prevalence of side effects of prolonged low or moderate dose opioid therapy with concomitant benzodiazepine and/or antidepressant therapy in chronic non-cancer pain. Pain Phys. 2009; 12: 45-9.
11. Ernst ME, Lyer SS, Doucette WR. Drug-related problems and quality of life in arthritis and low back pain sufferers. Val Health 2003; 6: 135-40.
12. Mcdermott M, Smith B, Elliott A, Bond C, Hannaford P, Chambers W. The use of medication for chronic pain in primary care, and the potential for intervention by a practice-based pharmacist. Fam Prac. 2005; 23: 46-52.
13. Kanjanarat P, Winterstein A, Johns T, Hatton R, Gonzalez-Rothi R, Segal R. Nature of preventable adverse drug events in hospitals. Am J Health Syst Pharm. 2003; 60: 1750-9.
14. Brvar M, Fokter N, Bunc M, Mozina M. The frequency of adverse drug reaction related admissions according to method of detection, admission urgency and medical department specialty. BMC Clin Pharmacol. 2009; 9-12.
15. Furlan AD, Sandoval JA, Mailis-Gagnon A, Tunks E. Opioids for chronic noncancer pain: A meta-analysis of effectiveness and side effects. Can Med Assoc J. 2006; 174: 1589-94.
16. Deshpande A, Furlan A, Mailis-Gagnon A, Atlas S, Turk D. Opioids for chronic low-back pain. Cochrane Database of Systematic Reviews. 2007; 3: 49-59.
17. Grahmann PH, Jackson KC,2nd, Lipman AG. Clinician beliefs about opioid use and barriers in chronic nonmalignant pain. J Pain & Pallia Care Pharmacother. 2004; 18: 7-28.
18. Pharmaceutical Care Network Europe Foundation. Classification for Drug related problems V 6.2. [online]. 2010. [cited 2012, January]. Available from: http://www.pcne.org/sig/drp/documents/drp/ PCNE%20classification%20V6-2.pdf.
19. Chang J and et al. Impact of disease severity and gastrointestinal side effects on the health state preferences of patients with osteoarthritis. Arthri & Rheu. 2005; 52: 2366–75.
20. Cuevas V, Briz E, Chorro M. Pharmacist intervention reduces gastropathy risk in patients using NSAIDs: On behalf of the NSAID induced Gastropathy Prevention Programme Group. Pharm World Sci. 2008; 30: 947-54.
21. McCracken LM, Hoskins J, Eccleston C. Concerns about medication and medication use in chronic pain. J Pain. 2006; 7: 726-34.
22. Palos GR, Mendoza TR, Cantor SB, Aday LA, Cleeland CS. Perceptions of analgesic use and side effects: What the public values in pain management. J Pain & Symp Manage. 2004; 28: 460-73.
